Till sidans topp

Sidansvarig: Webbredaktion
Sidan uppdaterades: 2012-09-11 15:12

Tipsa en vän
Utskriftsversion

Ultralow Dose of Naloxone… - Göteborgs universitet Till startsida
Webbkarta
Till innehåll Läs mer om hur kakor används på gu.se

Ultralow Dose of Naloxone as an Adjuvant to Intrathecal Morphine Infusion Improves Perceived Quality of Sleep but Fails to alter Persistent Pain: A Randomized, Double-blind, Controlled Study.

Artikel i vetenskaplig tidskrift
Författare Linda Block
Christopher Lundborg
Jan Bjersing
Peter Dahm
Elisabeth Hansson
Björn Biber
Publicerad i The Clinical journal of pain
Volym 31
Nummer/häfte 11
Sidor 968–975
ISSN 1536-5409
Publiceringsår 2015
Publicerad vid Institutionen för kliniska vetenskaper, Avdelningen för anestesiologi och intensivvård
Institutionen för neurovetenskap och fysiologi, sektionen för klinisk neurovetenskap och rehabilitering
Institutionen för medicin, avdelningen för reumatologi och inflammationsforskning
Sidor 968–975
Språk en
Länkar dx.doi.org/10.1097/AJP.000000000000...
Ämneskategorier Anestesi och intensivvård

Sammanfattning

This randomized, cross-over, double-blind, controlled study of continuous intrathecal morphine administration in patients with severe, long-term pain addresses whether the supplementation of low doses of naloxone in this setting is associated with beneficial clinical effects. All of the study subjects (n=11) provided informed consent and were recruited from a subset of patients who were already undergoing long-term treatment with continuous intrathecal morphine because of difficult-to-treat pain. The patients were (in a randomized order) also given intrathecal naloxone (40 ng/24 h or 400 ng/24 h). As control, the patients' ordinary dose of morphine without any additions was used. The pain (Numeric Rating Scale, NRS) during activity, perceived quality of sleep, level of activity and quality of life as well as the levels of several pro- and anti-inflammatory cytokines in the blood were assessed. The pre-study pain (NRS during activity) in the study group ranged from 3 to 10. 64% of the subjects reported improved quality of sleep during treatment with naloxone at a dose of 40 ng/24 hours compared with 9% with sham treatment (P=0.024). Although not statistically significant, pain was reduced by 2 NRS steps or more during supplemental treatment with naloxone in 36% of subjects when using the 40 ng/24 hours dose and in 18% of the subjects when using a naloxone 400 ng/24 hours dose. The corresponding percentage among patients receiving unaltered treatment was 27%. To conclude, the addition of an ultralow dose of intrathecal naloxone (40 ng/24 h) to intrathecal morphine infusion in patients with severe, persistent pain improves perceived quality of sleep. We were not able to show any statistically significant effects of naloxone on pain relief, level of activity or quality of life.This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivitives 3.0 License, where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially. http://creativecommons.org/licenses/by-nc-nd/3.0.

Sidansvarig: Webbredaktion|Sidan uppdaterades: 2012-09-11
Dela:

På Göteborgs universitet använder vi kakor (cookies) för att webbplatsen ska fungera på ett bra sätt för dig. Genom att surfa vidare godkänner du att vi använder kakor.  Vad är kakor?